Actuate Therapeutics Stock Forecast
NASDAQ: ACTUHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ACTU analyst consensus
Consensus (3 analysts)
none
Avg. price target
$11.68+1814.13%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Actuate Therapeutics (2026-10-09), 3 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $11.68, with a high estimate of $15.05 and a low estimate of $8.00. The average target implies upside of 1814.1% from the current price of $0.6102.
The spread between the highest and lowest targets is 88.1%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ACTU.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 3 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $8.00 | +1211.05% |
| Average target | $11.68 | +1814.13% |
| High target | $15.05 | +2366.40% |